Finally, as a real-world clinical study, long-term follow-up is required to obtain more treatment data, such as PD-1 or PD-L1 intensity of tumor tissues and follow-up imaging data to assess responses of patients with BoM to treatment, which may be conducive to identifing biomarkers of BMAs plus immunotargeted therapy for patients with HCC and BoM. This evidence concerns the gene CD274 and hepatocellular carcinoma.